SCD1 was previously shown to participate in aberrant lipid metabolism and promoted cell growth in lung cancer (32); therefore, its genetic and pharmacological inhibition could sensitize STK11/KEAP1 co-mutant cells to ferroptosis induction even in vivo. The gene discussed is KEAP1; the disease is lung carcinoma.